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Background and Aims: Pathological high amplitude of beta oscillations is thought as
the underlying mechanism of motor symptoms in Parkinson’s disease (PD), in particular
with regard to bradykinesia. In addition, abnormality in a neurophysiological phenomenon
labeled sensory attenuation has been found in patients with PD. The current study
explored the hypothesis that the abnormal sensory attenuation has a causal link with
the typical abnormality in beta oscillations in PD.
Methods: The study tested sixteen right-handed patients with a diagnosis of PD and 22
healthy participants, which were matched by age and gender. Somatosensory evoked
potentials were elicited through electrical stimulation of the median nerve at the wrist.
Electrical activity was recorded at the scalp using a 128 channels EEG. Somatosensory
evoked potentials were recorded in 2 conditions: at rest and at the onset of a voluntary
movement, which was a self-paced abduction movement of the right thumb.
Results: Healthy participants showed a reduction of the N20-P25 amplitude at the
onset of the right thumb abduction compared to the rest condition (P < 0.05). When
patients were OFF medication, they showed mild reduction of the N20-P25 component
at movement onset (P < 0.05). On the contrary, they did show greater attenuation of the
N20-P25 component at the onset of movement compared to the rest condition when ON
medication (P < 0.05). There was no significant evidence of a link between the degree
of sensory attenuation and the change in beta oscillations in our cohort of patients.
Conclusion: These results confirmed a significant link between dopaminergic
modulation and sensory attenuation. However, the sensory attenuation and beta
oscillations were found as two independent phenomena.
Keywords: Parkinson’s disease, sensory attenuation, beta power, bradykinesia, motor symptoms
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INTRODUCTION
Several studies have showed that sensory afferents are reduced
prior to and during movement (1–4). This phenomenon is
denominated sensory attenuation (SA) or sensory gating.
A recent theoretical framework, labeled active inference,
proposed that SA prior to and during active movement is an
essential mechanism that allow to move (5).
This model of movement initiation hypothesizes that the
brain needs to perceive when sensory information is uncertain
and must down weight these external sensations to top-
down predictions. In line with this hypothesis, the movement
initiation is a consequence of fulfilling prior expectations about
proprioceptive sensations. In other words, the movements are
allowed by the transition from one sensory state to another.
According to this model, an impairment to correctly initiate or
maintain a voluntary movement might be due to an abnormality
of SA (6).
It is still unknown if the pathophysiology of bradykinesia in
Parkinson’s disease (PD) is due to a deficit in SA. The latter is
thought to be linked with pathology in reducing the precision of
the somatosensory expectations (6).
The SA can be tested in two different fields: physiological
and perceptual (7). The neurophysiological measure of SA
is represented as a reduction in amplitude of somatosensory
evoked potentials (SEPs) components at the onset of a voluntary
movement compared with a rest condition (7).
SA is expected to be reduced in PD and improved with
medical treatment. Indeed, SA prior to and during movement
(as measured by a decrease in the amplitude of N20-P25
component of SEPs elicited by median nerve stimulation) has
been found significantly reduced in PD patients OFF medication
(8). Moreover, SA was normalized by dopaminergic medication
(8). Of note, an attenuation of the N20-P25 component at the
onset of voluntary movements in healthy participants (8).
This study aimed to replicate results of the previous
study (8) in a completely naïve group of PD patients.
The prediction was an interaction in the SEPs amplitude
between group and time with the SEPs being more greatly
attenuated in healthy controls at the onset of active movement
than the patients’ group in OFF state. Furthermore, it
was predicted that there would not be any significant
differences in SA between healthy participants and patients
ON medication.
A second aim was to test whether SEPs attenuation was
modulated as a function of disease and voluntary movement.
In other words, it was tested if there was a correlation between
the difference in N20-P25 amplitude between baseline and
movement condition with measurements of bradykinesia using
the Unified Parkinson’s Disease Rating scale (UPDRS) (9) as well
as parametric measures of the tapping through a cybernetic glove.
The prediction was that SEPs attenuation would correlate with
movement such that the faster and more vigorous movements
would be positively correlated with the degree of the SA. It
was predicted that across subjects the lower (better) the UPDRS
scores and the less slowing and decrement in amplitude of
tapping measured by cyberglove, the greater the SA measured at
movement onset. These results would be further support of the
pathophysiological role of SA in the contest of bradykinesia.
Notably, the active inference theory makes more detailed
predictions (10). It predicts that SA will be driven by a change
in the precision of the sensory expectation, with lower precision
leading to greater SEPs attenuation.
The second part of the study explored if SA modulations
would be correlated with modulation in beta power in the
sensorimotor cortex, which decrease prior to and during
movement (11, 12).
Recently, Tan et al. (13) proposed a novel theory based
on the functional role of sensorimotor post-movement beta
synchronization (PMBS). This theory linked theoretical models
of motor control related to a phenomenon called uncertainty and
neurophysiological measures of sensorimotor activity. Indeed,
voluntary movements stimulate peripheral sensory receptors
providing sensory feedback of the movement action.
Adams et al. (10) tested a model hypothesizing that the
predicted sensory consequences of a movement are compared to
the actual sensory input. These authors calculated the prediction
error by the difference between the predicted and actual sensory
input. The prediction error is a measure used to make the
forward model able to perform more accurate future predictions.
Estimations of the uncertainty in the motor prediction and the
uncertainty of the actual sensory input are required to calculate
the importance of any prediction errors (14).
Tan et al. (13) have proposed modalities to manipulate the
uncertainty. In addition, these authors predicted that PMBS
would be correlate with the uncertainty rather than with the
movement error. The PMBS amplitude over sensorimotor cortex
was found to be characterized by negative correlation with the
variable of uncertainty. Consequentially, this result supports a
novel functional role of PMBS linking beta oscillations to the
uncertainty of the parameters underlying the motor control.
In other words, sensorimotor beta oscillatory power might
be the neurophysiological mechanism allowing to estimate of
uncertainty or causally modulating the uncertainty.
Palmer et al. (15) highlighted that this potential correlation
between PMBS and sensory uncertainty might mean that beta
oscillatory activity is a potential candidate for this sensory gating
phenomenon. If beta oscillationsmodulation would be correlated
with the time course of SEPs attenuation, this would be evidence
that there might be a potential link between beta oscillatory
activity and SA.
This finding is particularly relevant for the application of this
theoretical account to explain akinesia and bradykinesia. In PD
beta oscillations in the motor network and in the STN are higher
during rest. Consequentially, pathological higher beta oscillations
have been causally implicated in movement impairment rather
than being just an epiphenomenon of the diseased state (16).
One theory therefore is that patients with PD have high
sensory precision such that when they decide to move, they
cannot attenuate this precision enough to allow the influence of
top-down proprioceptive predictions to supersede. This theory is
supported by our study, which has demonstrated decreased SA
in patients diagnosed with PD compared to age-matched healthy
controls (8, 17). Furthermore, dopaminergic treatment acted to
Frontiers in Neurology | www.frontiersin.org 2 September 2019 | Volume 10 | Article 1001
Macerollo et al. Somatosensory Integration in Parkinson’s Disease
normalize SA in PD patients, which suggests this may be one of
the mechanisms which can explain the improvement in motor
symptoms under this class of medication (8).
Here, it was tested if the specific time course of the SA is
correlated with modulations in beta power during movement
execution. The prediction was that modulations in beta power
will be positively correlated with the time course of SEPs
modulation. If this is the case, it will establish a statistical
dependency between beta power and SA.
METHODS
Sixteen patients diagnosed with idiopathic PD (10 males, 6
females; mean age, 68 years; range, 52–79 years; Table 1) and 22
age and sex matched healthy participants (14 males, 8 females;
mean age, 67 years; range, 50–80 years) were involved in the
study. Control subjects were recruited from a pool of healthy
subjects of the University College of London. This group of
participants were not diagnosed with any medical disorder and
they were not on medication.
PD patients were recruited from the Movement Disorders
Clinics at the National Hospital of Neurology and Neurosurgery.
Idiopathic PD was diagnosed according to the UK PD Society
Brain Bank criteria (18) and further confirmed by abnormal
dopamine transporter SPECT in all patients.
TABLE 1 | Clinical and demographic characteristics of patients with Parkinson
disease (Mo, months; y, years; UPDRS, Unified Parkinson’s Disease Rating Scale;
SD, standard deviation; L, L-DOPA; D, Dopamine agonist).
Age
(y)
Gender Disease
duration
(y)
Motor
UPDRS
upper limbs
bradykinesia
items
OFF state
Motor
UPDRS
upper limbs
bradykinesia
items
ON state
Treatments
1 72 M 11 11 6 L
2 75 F 4 9 5 L
3 61 M 2 6 3 L
4 75 M 5 11 5 L
5 77 F 10 9 5 L
6 68 F 4 6 3 L
7 56 M 4 8 3 L
8 70 F 6 6 3 L+D
9 69 M 6 9 4 L+D
10 79 F 12 10 6 L+D
11 68 F 10 12 6 L+D
12 52 M 10 12 6 L+D
13 62 M 3 8 3 L+D
14 68 M 8 12 9 L+D
15 72 M 5 8 3 L+D
16 68 M 5 8 3 L+D
Mean
± SD
68.1
± 6.9
F8/M12 6.5
± 2.9
9 ± 2 4.3 ± 1.7
Participants did not have disabling tremor. None of the
patients had cognitive decline. PD patients were on levodopa
medication and/or on dopaminagonists.
Participants were right-handed.
The study was approved by the East of Scotland Research
Ethics Service. Written informed consent was obtained from
all participants.
Clinical disease severity was assessed with the motor section
(items 3.1–3.18) of the UPDRS (9). The clinical assessment was
performed in the ON as well as OFF state in each patient.
The amplitude and the frequency of a minute right hand
tapping test with the Cyber Glove was recorded in both
pharmacological states.
To reach the OFF state, patients were required not to take
levodopa for at least 12 h and dopamine-agonists for at least 24 h
prior to testing. Patients were assessed in the ON state 1 h after
taking levodopa or 2 h after taking dopamine agonists (Table 1).
Procedure and Experimental Design
Participants were seated in a comfortable armchair with hands
relaxed on the armrest of the chair and their eyes closed. Two
electrodes were placed on the surface of the wrist. The anode
was placed over the median nerve at the wrist and the cathode
2 cm proximal to the anode. SEPs were elicited by electrical
stimulation of themedian nerve at the right wrist using a constant
current square-wave pulse (0.2ms duration). The intensity of the
stimulation at threshold (slight thumb twitch) was identified and
then increased by 1mA to produce a definite thumb twitch. The
intensity remained the same throughout the experiment.
Electrical activity was recorded at the scalp using a 128
channels Biosemi ActiveTwo AD-box EEG. EEG was recorded
at a sampling rate of 2,048 Hz.
Surface electromyography (EMG) of the right abductor
pollicis brevis (APB) was monitored simultaneously.
SEPs were recorded in three conditions in a single session.
In the baseline condition, the subjects were relaxed and
instructed not to react to the stimulus. The frequency of the
median nerve stimulation was 0.5Hz. Subjects received 500
stimulations in this condition.
In the movement condition, subjects were instructed to
make a self-paced abduction movement of the right thumb
with a frequency of around a movement every second. At
the onset of the movement, the median nerve stimulus was
automatically triggered. The frequency of movements was
recorded. Participants made 500 thumb abductions.
In the rest condition, the subjects were relaxed and instructed
not to react to the stimulus. In distinction to the baseline
condition here the median nerve stimulations were given at
precisely the same times as the self-paced movements recorded
from the movement condition.
Data Analysis
Measure of SEPs Components and SA
EEG data analyses were performed in MATLAB 2013b (Math
Works, Natick, MA, USA) using the software Statistical
Parametric Mapping (SPM12, Wellcome Department of Imaging
Neuroscience, London, UK).
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The SEPs produced at movement onset has previously been
employed to assess the degree of SA during active movement.
Indeed, SEPs elicited by stimulation at this time point is
not confounded by any possible effect of the afferent signal
produced by the movement. The initial analysis was focused on
modulations in the SEPs components, specifically the amplitude
of the N20 and P25 as a function of group (PD patients
ON medications, PD patients OFF medication and healthy
participants). The peak-to-peak amplitude of the N20-P25
component was measured for each participant. EEG data were
analyzed in SPM12.
The oﬄine data were high-passed filtered at 0.1Hz and,
then, epoched to the time of the onset of the median nerve
stimulation taking the 100ms before stimulation and 250ms after
the stimulation. The data were baseline corrected by subtracting
the average of the signal in a window from 20 to 5ms prior to
median nerve stimulation.
Artifacts exceeding 100mV were manually rejected.
SEPs were averaged across the 500 trials of each condition.
The baseline condition was the reference to select the appropriate
channels to see N20 and P25. The electrodes over sensorimotor
cortices were selected based on electrodes contralateral to the
stimulated wrist that showed a negative peak at around 20ms and
a positive peak around 25–35ms after the stimulus.
Then, the data from the selected channels were averaged
and the amplitude and the time data points of N20 and P25
were measured. These electrodes and time points were used to
calculate the amplitude of the N20 and P25 in the other two
conditions—rest condition and movement condition. Note that
the choice of electrodes and time points from an independent
condition removed selection bias in the two experimental
conditions of interest.
The SA was measured through the difference in the absolute
amplitude of the peak N20-P25 between the rest and movement
onset conditions was calculated.
Analysis of Parametric Measures of
Tapping and Quantification of Bradykinesia
The finger-tapping performed using the cyber glove was recorded
through aMatlab script. The amplitude and the frequency of each
tapping movement in a minute of interval time were calculated
using Welch’s power spectral density estimate of the time series
of the tapping as recorded by the CyberGlove. The data were
then averaged, and the peak amplitude and frequency at the peak
amplitude of the tapping was taken for each pharmacological
state of each patient. These were the parametric measures
of tapping.
The regression analysis between SA and parametric measures
of tapping was performed to test the hypothesis of a correlation
between dopaminergic modulation of SA and dopaminergic
improvement of bradykinesia.
Analysis of Beta Power in Movement and
Rest Condition
In healthy subjects, power in beta oscillations is expected to be
attenuated prior to the thumb movement and augmented once
the movement has ended (12).
After raw data conversion, EEG data were re-referenced
by subtracting the average signal from two external electrodes
attached to the subjects’ earlobes from the signal from each
EEG electrode. Data were high pass (0.1Hz) filtered and down-
sampled to 400 Hz.
A trigger was sent to the EEG system at the time of every
median nerve stimulus. The data were epoched to the time of
median nerve stimulation, taking the 1,000ms before the onset
and 1,000 ms after.
The different experimental blocks were merged into a
single file.
For the time–frequency analysis, the power of the EEG signal
at each frequency from 1 to 99Hz in steps of 2 was estimated
using the Morlet spectral estimation in SPM. The data were
rescaled using a logarithmic transformation and averaged across
all trials.
The time–frequency data were averaged over the same
electrode channels selected for the SEPs analysis on the scalp
map to investigate the modulation of beta power in each
condition (rest and movement) for each subject and in each
pharmacological state for each patient.
Subsequently, the time-frequency images for the rest
condition for each subject were averaged across all subjects and
three time’ windows. The latter corresponded to the three phases
of beta oscillations modulation with median nerve stimulation in
the rest condition and were calculated as background (between
180 and 625ms before the stimulus), suppression (between
165 and 378ms after stimulus) and rebound (between 535
and 980 ms).
The beta power, obtained by averaging over the frequency of
15–25Hz, was then averaged over each selected time window
across subjects of each group to have a value of beta power for
each time window per group per condition. Subsequently, a value
of beta power modulation for each group and each time window
was obtained through a subtraction of beta power value between
rest and movement condition.
The value of beta power modulation was then regressed
against the amplitude of SA per group per time window.
Finally, a regression analysis was performed between the
amplitude of beta power and amplitude of SEPs for each group
per time window per condition.
RESULTS
SEPs Components and SA
The averaged SEPs over our ROI (channels over the
somatosensory cortex) across participants for PD patients
OFFmedication, ONmedication, and control subjects are shown
in Figure 1.
Repeated measures ANOVAwith the group (ON vs. OFF) and
condition (rest vs. movement) as factors showed a significant
effect of the condition [p < 0.05; F(1,30) = 39.46; Eta
2 =
0.537] and a significant interaction between condition and
pharmacological state [p < 0.05; F(1,30) = 6.33; Eta
2 = 0.157].
Post-hoc pairwise comparisons revealed a significant difference
between N20-P25 peak to peak amplitude between the rest
condition and movement condition [p < 0.05; t(30) = 5.85].
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FIGURE 1 | Average SEPs across participants recorded from the left somatosensory cortex for PD patients OFF medication, ON medication, and control subjects.
Solid lines show data for median nerve stimulation given at movement onset and dotted lines during baseline. The gray lines show the mean time of the peaks of the
N20 and P25 components.
As expected, healthy participants showed attenuation of
the N20-P25 amplitude at movement onset (2.13 ± 1.87)
compared to the rest condition (4.8 ± 2.84) [P < 0.05;
t(21) = 7.45, Figure 2A].
PD patients OFF medication showed mild attenuation of
the N20-P25 component at movement onset (3.99 ± 2.31)
compared to rest condition (5.03 ± 3.29) [P < 0.05; t(15) =
2.52; Figure 2B]. This group showed greater attenuation of
the N20-P25 component at the onset of movement (2.59 ±
1.79) compared to the rest condition (5.02 ± 2.94) when ON
medication [P < 0.05; t(15) = 5.95; Figure 2C].
There was a significant difference in the amplitude of N20-P25
peak during the movement condition between OFF state (3.99±
2.31) and ON state (2.59± 1.79) [p=< 0.05; t(15) = 3.32] with a
smaller amplitude in the ON state.
There was no difference in the N20-P25 amplitude during the
rest condition betweenOFF state (5.03± 3.29) andON state (5.02
± 2.94) [p ≥ 0.05; t(15) = 0.017].
The SA (defined as difference in the amplitude of N20-P25
peak between rest condition and movement condition) showed
a significant difference between OFF (1.29 ± 1.55) and ON state
(2.42± 1.55) in PD patients [p≤ 0.05; t(15) =−3.28] with greater
SA in ON state (Figure 2D).
There was no difference in the SA between PD patients in ON
state (2.42 ± 1.55) and healthy subjects (2.74 ± 1.61) [p ≥ 0.05,
t(36) =−0.46] (Figure 2D).
Having shown that SA was modulated by dopaminergic
treatment and that SA was significantly attenuated in PD patients
ON medication, it was tested if the severity of right arm
bradykinesia was correlated with the degree of SA. In this regard,
there was no statistically significant correlation between SA
and UPDRS scores (R2 = 0.001, p = 0.893 OFF medication
(Figure 3A) and R2 = 0.001, p = 0.924 ON medication
(Figure 4A) as well as between SA and frequency of the fingers
tapping (R2 = 0.059, p = 0.330 OFF medication (Figure 3B)
and R2 = 0.002, p = 0.867 ON medication (Figure 4B) or
amplitude of the fingers tapping (R2 = 0.06, p = 0.323
OFF medication (Figure 3C) and R2 = 0.008, p = 0.718 ON
medication (Figure 4C).
After having tested the hypothesis of a potential correlation
between SA and each measure of bradykinesia in the individual
pharmacological state, a potential correlation between the
dopaminergic modulation of SA and the dopaminergic
modulation of each measure of bradykinesia was investigated.
In other words, it was tested if there was a correlation between
SA changes between OFF and ON states and changes of each
measure of bradykinesia between OFF and ON states. There
was no statistically significant correlation between dopaminergic
modulation of SA and changes of UPDRS scores (R2 = 0.016,
p = 0.616) (Figure 5A). There was a significant correlation
between dopaminergic modulation of SA and changes of
frequency of the fingers tapping (R2 = 0.623, p < 0.001)
(Figure 5B). However, there was not significant correlation with
the amplitude of the finger tapping at this frequency (R2 = 0.021,
p= 0.562) (Figure 5C).
Beta Oscillations Modulation
Having demonstrated that there was a modulation of SEPs over
condition, the second aimwas to test if the SAwas correlated with
modulations in beta oscillations over the sensorimotor cortex.
Firstly, it was tested the hypothesis that healthy controls and
PD patients showed a modulation of beta power as function
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FIGURE 2 | Mean amplitude of the N20-P25 component for each condition for control subjects (A), PD patients OFF medication (B), ON medication (C). Error bars
show standard error of the means. Mean difference of the N20-P25 amplitude between rest condition and movement condition in PD patients OFF medication, ON
medication and controls (D). *p < 0.05.
of time in each experimental condition. The prediction was to
find power in beta oscillations attenuated prior to the thumb
movement and a rebound at the end of the movement. After
averaging the time-frequency images across subjects for each
group, the changes of the beta power spectrum (interval of
frequency at 15–30Hz) as function of time in each condition
were showed. Beta power was clearly evident prior to movement
in the baseline period, suppressed in the motor preparation
and execution period and, finally, rebounded at the end of the
thumb movement.
The modulation of beta oscillations in the rest condition
averaged across subjects for each group is showed in the Figure 6.
Following the qualitative analysis, a quantitative analysis of
the beta oscillations was performed in three time’ windows
selected as explained in the methods section. The three
times windows corresponded to the three phases of beta
oscillations modulation calculated as background (between
180 and 625ms before the stimulus), suppression (between
165 and 378ms after stimulus) and rebound (between 535
and 980 ms).
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FIGURE 3 | Regression analysis between sensory attenuation (SA) and measures of bradykinesia [UPDRS score (A), frequency of fingers tapping (B) and amplitude
of fingers tapping (C)] in PD patients in OFF state.
FIGURE 4 | Regression analysis between sensory attenuation (SA) and measures of bradykinesia [UPDRS score (A), frequency of fingers tapping (B) and amplitude
of fingers tapping (C)] in PD patients in ON state.
FIGURE 5 | Regression analysis between dopaminergic changes of sensory attenuation (SA) and dopaminergic changes of each measure of bradykinesia [UPDRS
score (A), frequency of fingers tapping (B) and amplitude of fingers tapping (C)]. The dopaminergic changes of each variable were calculated through the difference
between OFF and ON values for each variable.
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FIGURE 6 | Modulation of beta power changes as function of time at rest in each group of participants (PD ON, PD OFF, Healthy Subjects).
The quantitative analysis confirmed that the amplitude of
beta oscillations was different as function of time. Indeed, beta
oscillations amplitude showed a significant statistical difference
in each group and in each condition over the 3 different timing
windows (Figure 7).
Repeatedmeasures 2× 2× 3 ANOVAwith the group [healthy
controls vs. patients (ON)], condition (rest vs. movement) and
phase (background, suppression and rebound) as factors did not
show a significant effect of group [p > 0.05; F(1,36) = 0.040;
Eta2 = 0.001]. There was a significant effect of the condition
[p < 0.05; F(1,36) = 34.88; Eta
2 = 0.493] and a significant
interaction between condition and group [p < 0.05; F(1,36)
= 8.739; Eta2 = 0.195]. There was a significant effect of the
phase [p < 0.05; F(1,36) = 91.185; Eta
2 = 0.717]. There was
no significant interaction between phase and group [p > 0.05;
F(1,36) = 2.834; Eta
2 = 0.073]. There was a significant interaction
between condition and phase [p < 0.05; F(1,36) = 15.047;
Eta2 = 0.295].
Post-hoc pairwise comparisons with Bonferroni corrections
did not reveal significant difference between the two groups
(healthy participants vs. PD ON state) in the rest condition in
each phase: background [p > 0.05, t(36) = 1.090], suppression
[p > 0.05, t(36) = 0.491] and rebound [p > 0.05, t(36) = 1.235].
The two groups did not show significant difference neither in the
movement condition in each phase: background [p > 0.05, t(36)
= −0.645], suppression [p > 0.05, t(36) = −0.579] and rebound
[p > 0.05, t(36) =−0.370].
Furthermore, post-hoc pairwise comparisons showed
significant differences between the rest and movement condition
in the background phase [p < 0.05, t(37) = −5.356], suppression
[p <0.05, t(37) =−4.156] and rebound [p <0.05, t(37) =−6.795]
over the two groups.
Repeatedmeasures 2× 2× 3 ANOVAwith the group [healthy
controls vs. patients (OFF)], condition (rest vs. movement) and
phase (background, suppression and rebound) as factors did not
show an effect of the group [p > 0.05; F(1,36) = 0.0765; Eta
2 =
0.021]. There was a significant effect of condition [p< 0.05; F(1,36)
= 58.04; Eta2 = 0.617] and a significant interaction between
condition and group [p < 0.05; F(1,36) = 7.931; Eta
2 = 0.181].
There was a significant effect of the phase [p < 0.05; F(1,36)
= 98.454; Eta2 = 0.732]. There was no significant interaction
between phase and group [p> 0.05; F(1,36)= 2.366; Eta
2= 0.062].
There was a significant interaction between condition and phase
[p < 0.05; F(1,36) = 20.392; Eta
2 = 0.362].
Post-hoc pairwise comparisons with Bonferroni corrections
did not reveal significant difference between the two groups
(healthy participants vs. PD OFF state) in the rest condition in
each phase: background [p > 0.05, t(36) = 1.446], suppression
[p > 0.05, t(36) = 1.125] and rebound [p > 0.05, t(36) = 1.725].
The two groups did not show significant difference neither in the
movement condition in each phase: background [p > 0.05, t(36)
= 0.112], suppression [p > 0.05, t(36) = 0.217] and rebound [p >
0.05, t(36) = 0.484].
Furthermore, post-hoc pairwise comparisons showed
significant differences between the rest and movement condition
in the background phase [p < 0.05, t(37) = −6.739], suppression
[p <0.05, t(37) =−5.002] and rebound [p <0.05, t(37) =−8.876]
over the two groups.
Having found a modulation of beta oscillations amplitude as
function of time, the subsequent aim was to test if there was a
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FIGURE 7 | Mean amplitude of beta oscillations for each condition and each group in three selected time windows. These corresponded to the three phases of beta
oscillations modulation calculated as background (between 180 and 625ms before the stimulus), suppression (between 165 and 378ms after stimulus) and rebound
(between 535 and 980ms).
correlation between beta oscillations amplitude changes across
the two conditions and SEPs changes across the two conditions,
which was the measure of SA.
This correlation analysis was performed separately for each
time window in each group of participants.
There was no evidence that SA and beta oscillations amplitude
modulation were correlated in PD patients ON state and healthy
subjects. Indeed, healthy participants did not show a significant
correlation between beta oscillations amplitude modulation and
SA in background phase (R2 = 0.04, p = 0.51), suppression
phase (R2 = 0.08, p = 0.24) or the rebound phase (R2 =
0.06, p = 0.37). The absence of a correlation between these
two neurophysiological phenomena was evident also in the PD
patients group in ON (background phase, R2 = 0.11, p = 0.56;
suppression phase,R2= 0.07, p= 0.73; rebound phase,R2= 0.14,
p= 0.43) as well as in OFF state (background phase, R2 = 0.005, p
= 0.41; suppression phase, R2 = 0.003, p = 0.31; rebound phase,
R2 = 0.006, p= 0.15) (Figure 8).
Having not found evidence for a relationship between
the degree of SA and the changes in beta power, it was
tested if there was a relationship between beta oscillations
amplitude and SEPs amplitude. The two measures were
measured as a general phenomenon and not as function of the
group. Therefore, we investigated if beta oscillations amplitude
and SEPs amplitude were correlated in two groups: healthy
subjects + PD in OFF state and healthy subjects + PD in
ON state.
In the first analyzed group including healthy and PD patients
OFF medication, a positive correlation between beta power
magnitude and SEPs amplitude was found in the rest condition
in all selected time windows (background phase, p = 0.02, R2 =
0.139; suppression phase, p= 0.01, R2 = 0.162; rebound phase, p
= 0.00, R2 = 0.220). In other words, lower amplitude of SEPs was
correlated with lower beta power amplitude.
However, this positive correlation seemed to be driven
by the PD patients OFF medication. Indeed, when the
two groups of participants were analyzed separately, healthy
subjects did not show any correlation between beta oscillations
amplitude and SEPs amplitude at rest in each time window
(background phase, p = 0.21, R2 = 0.07; suppression phase,
p = 0.16, R2 = 0.09; rebound phase, p = 0.06, R2 =
0.159). Whereas, the PD OFF medication showed a significant
correlation between the two measures at rest in all time
windows (background phase, p = 0.02, R2 = 0.304; suppression
phase, p = 0.01, R2 = 0.335; rebound phase, p = 0.01,
R2 = 0.371) (Figure 9).
In the movement condition the group including healthy
subjects and PD OFF patients still showed a significant
correlation between the two conditions in the background timing
window (p = 0.03, R2 = 0.113) and a statistical trend in the
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FIGURE 8 | Correlation analysis beta power modulation and sensory attenuation individually in the three groups of participants.
suppression phase (p = 0.08, R2 = 0.08) and in the rebound
phase (p = 0.08, R2 = 0.08). Interestingly, this correlation was
driven by the PD OFF patients. Indeed, when the two groups of
participants were analyzed separately the significant correlation
was kept only by PD OFF medication. The control group did not
show any correlation in all time windows (background phase, p=
0.41, R2 = 0.03; suppression phase, p= 0.69, R2 = 0.008; rebound
phase, p= 0.46, R2 = 0.02), whereas PD OFFmedication showed
significant correlation between beta oscillations modulations and
SA in the three time windows (background phase, p= 0.01, R2 =
0.363; suppression phase, p= 0.01, R2 = 0.351; rebound phase, p
= 0.01, R2 = 0.354).
In the second analyzed group including healthy participants
and PD patients ON medication a statistical trend of the
correlation between beta oscillations amplitude and SEPs
amplitude was found in the first two times windows (background
phase, p = 0.09, R2 = 0.07; suppression phase, p = 0.07, R2 =
0.08) and a significant correlation in the rebound window in the
rest condition (p = 0.01, R2 = 0.144). However, it is likely that
this result was driven by the power of this bigger sample.
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FIGURE 9 | Correlation analysis between beta power and SEPs amplitude at rest and during movements in healthy subjects and PD patients Off medication.
When the two groups of participants were analyzed separately,
neither groups showed any significant correlations between the
two measures in the rest condition in any time windows. Healthy
subjects did not show a significant correlation in the background
phase (p= 0.21, R2 = 0.07) or in the suppression phase (p= 0.16,
R2 = 0.09). There was a statistical trend in the rebound window
(p= 0.06, R2 = 0.159). PD patients ONmedication did not show
significant correlation in background phase (p= 0.62, R2 = 0.08),
suppression phase (p= 0.44, R2 = 0.06) and rebound phase (p=
0.40, R2 = 0.137) (Figure 10).
In the movement condition, there was no significant
correlation in all analysis (healthy participants+ PDON patients
and separately healthy subjects and PD ON). The combination
of healthy controls and PD patients in ON state showed the
following results: background phase, p = 0.69, R2 = 0.04;
suppression phase, p= 0.87, R2 = 0.001; rebound window in the
rest condition, p= 0.88, R2 = 0.001).
When the two groups of participants were analyzed separately,
neither groups showed any significant correlations between the
two measures in the rest condition in any time windows. Healthy
subjects’ group did not show a significant correlation in the
background phase (p = 0.41, R2 = 0.034) or in the suppression
phase (p = 0.69, R2 = 0.008). There was a statistical trend in
the rebound window (p = 0.46, R2 = 0.027). PD patients ON
medication did not show significant correlation in background
phase (p = 0.62, R2 = 0.017), suppression phase (p = 0.44, R2 =
0.043) and rebound phase (p= 0.40, R2 = 0.050) (Figure 10).
These results might be explainable by the presence of SEPs
attenuation in both groups at the onset of the movement.
Therefore, SEPs amplitude was lower at the onset of the
movement compared to the magnitude at rest but beta does not
change as function of condition, therefore the correlation was
not significant.
DISCUSSION
These results confirmed our previous study (8). A significant link
was found between dopaminergic modulation and SA. Indeed, at
movement onset PD patients off medication showed a lower SA
compared to PD patients ON medication. The mean difference
of the N20-P25 amplitude between rest condition and movement
condition was significantly different between PD patients OFF
medication and ON medication.
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FIGURE 10 | Correlation analysis between beta power and SEPs amplitude at rest and during movements in healthy subjects and PD patients ON medication.
This result of lower SA in PD patients OFF medication
is in line with previous studies that have shown abnormal
SA in PD (19, 20). It is important to consider that there
were critical differences in the task design. In previous studies
(19, 20), patients were tested making vigorous wrist flexion
and extension movements. In addition, SEPs were recorded
during continuous movement. In our study, subjects performed
a movement of the thumb and the median nerve stimuli was
delivered at the onset of the voluntary movement. Our results
supported the hypothesis that a failure in SA prior to movement
onset contributes to the difficulties in movement initiation
in PD.
In line with previous studies (12, 21), healthy subjects showed
changes in beta oscillations as attenuated prior the voluntary
movement and augmented once the movement has ended.
A potential correlation of SA with cortical beta oscillations
in the cohort of PD patients and age-matched healthy subjects
was hypothesized. The study was focused in understanding the
functional role of beta oscillations as it is well-known that PD
patients have a pathologically higher power of beta oscillations,
both in the cortex (16) and sub-cortically in the subthalamic
nucleus (16, 22–24). Of note, levodopa treatment (22, 23) and
subthalamic deep brain stimulation for PD (22, 23, 25, 26) are
associated with a decrease in beta power. On the other hand,
it is well known that stimulation of the subthalamic nucleus at
the beta frequency (15–30Hz) causes a slowing of movement in
patients with PD (27). Consequentially, the high amplitude of
beta oscillations in PD was proposed as a cause of bradykinesia
(16). However, the mechanism underlying this hypothesis is still
not clear.
This study provided evidence that physiological SA could be
the neurophysiological mechanism underlying the bradykinesia.
Therefore, if both these mechanisms (physiological SA and high
beta oscillations) have been hypothesized as underlying the
bradykinesia, a correlation between these two mechanisms was
proposed. Specifically, it was tested whether the modulation of
SA was correlated with the modulation of beta oscillations during
voluntary movements.
Our results did not show significant evidence of a modulation
of cortical beta oscillations driven by the sensory-motor cortex
on SA. This finding can be interpreted in two ways, either that
the cortical beta oscillations are not involved in modulation
of SA or that our groups’ size was not enough to reach the
statistical power.
Regarding the first possibility, although there is no direct
evidence of a potential link between cortical beta oscillations and
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SA, it is known that the beta oscillations plays important role
on the modulation of motor control. In particular, it has been
shown that the modulation of beta oscillations shows a particular
pattern during voluntary movements (12). This modulation of
beta oscillations takes place at the onset of voluntary movement,
when SA is also present. Consequentially, there is a rationale to
explore if the SA modulation is correlated with beta oscillations
modulation over the sensorimotor cortex. On the other hand,
the beta oscillations are present not only at the cortical level but
also at the subcortical level as in the basal ganglia, which were
not explored in this study. From the above, it was not possible
to determine whether or not subcortical beta oscillations play a
modulatory role on SA. In order to address this issue further, it
would be necessary to investigate SA in PD patients with STN-
DBS to test if there is a correlation with the abnormal beta
oscillations in STN, typically seen in this group of patients.
Regarding the second possibility, it is well known that a major
fault of scientific studies (including ours) is inadequate statistical
power. A larger number of subjects were required to adequate
power the studies because of increased variability of SA as well
as cortical beta oscillations in the patient population. Although
this is a major limitation for any conclusion about the mean of
potential link between SA and beta oscillations in patients with
PD, the fact that SA was replicated to be reduced in patients
with PD OFF dopaminergic treatment is noteworthy on its own.
Increased variability may have important implications in the
design and interpretation of future studies and may indeed be
related to pathophysiological mechanisms of PD.
The results of this study did not support the theory suggesting
that the modulation of physiological SA and modulation of
beta oscillations over the sensorimotor cortex are related.
However, it was confirmed the modulation of the two parameters
during voluntary movements. In particular, the two groups of
participants showed reduced beta power just prior to and during
the period of movement and transiently increased subsequent to
the end of the movement. This result is in line with previous
studies (28, 29). Furthermore, several studies showed evidences
that beta oscillations play a role in sensorimotor processing (30–
33). In this regard, Baker et al. (31) found that beta frequency
showed a coherence between proprioceptive afferents (Ia muscle
spindles) and forearm muscle activity, suggesting that beta
oscillations may have a role mainly in proprioceptive processing.
On the contrary, there was no coherence between muscle activity
and afferents relate to cutaneous receptors. However, Witham
et al. (33) did not find a difference in coherence with M1
between areas 1 and 3b, which are associated to cutaneous
receptive fields, and areas 3a and 2, which are associated with
proprioception (areas 3a and 2). Therefore, this study provided
evidence for a close link between the sensory and motor systems
via oscillatory synchronization and support previous hypotheses
that this pattern of activity may be important in coordinating
the processing of somatosensory information within its motor
context (32, 33).
The current study did not confirm a role of beta pattern
activity in coordinating the somatosensory integration at least in
terms of SA.
This study did not show a significant different amplitude in the
cortical beta oscillations between PD ON and healthy controls
as well as between PD OFF and healthy controls. Therefore,
these results bring under discussion the pathological role of
sensorimotor beta oscillations in PD. There is a need to be a
replication of the study on a larger group of PD patients to
confirm these results. Additionally, further studies are needs to
test a potential correlation between physiological SA and beta
oscillations generated in the basal ganglia with the aim to test
if modulation of SA is correlated with this other pattern of
beta activity.
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